|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 248.08 USD | -0.73% |
|
-4.98% | +8.57% |
| 11/07 | Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says | MT |
| 11/07 | BofA Securities Adjusts AbbVie Price Target to $276 From $234 | MT |
Company Valuation: AbbVie Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 239,371 | 285,707 | 273,605 | 314,021 | 403,830 | 438,306 | - | - |
| Change | - | 19.36% | -4.24% | 14.77% | 28.6% | 8.54% | - | - |
| Enterprise Value (EV) 1 | 306,225 | 339,749 | 320,176 | 375,610 | 463,570 | 493,309 | 484,733 | 472,471 |
| Change | - | 10.95% | -5.76% | 17.31% | 23.42% | 6.42% | -1.74% | -2.53% |
| P/E | 21x | 24.4x | 57x | 74.4x | 96.8x | 30.1x | 23.1x | 19.3x |
| PBR | 15.5x | 16.6x | 26.5x | 94.8x | -124x | 1,337x | 54.7x | 24.3x |
| PEG | - | 8.74x | -1x | -6.1x | -77.12x | 0x | 0.8x | 1x |
| Capitalization / Revenue | 4.27x | 4.92x | 5.04x | 5.57x | 6.6x | 6.52x | 6.02x | 5.6x |
| EV / Revenue | 5.46x | 5.85x | 5.89x | 6.67x | 7.58x | 7.34x | 6.66x | 6.04x |
| EV / EBITDA | 10.6x | 11x | 12.5x | 15.6x | 18.9x | 15x | 13.1x | 11.6x |
| EV / EBIT | 10.9x | 11.3x | 12.9x | 16.1x | 19.5x | 15.5x | 13.4x | 11.8x |
| EV / FCF | 13.9x | 14x | 14.5x | 21.1x | 26x | 16x | 14.4x | 13.6x |
| FCF Yield | 7.18% | 7.14% | 6.89% | 4.75% | 3.84% | 6.25% | 6.93% | 7.33% |
| Dividend per Share 2 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | 6.859 | 7.234 | 7.637 |
| Rate of return | 3.92% | 3.53% | 3.87% | 3.54% | 2.91% | 2.76% | 2.92% | 3.08% |
| EPS 2 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 8.241 | 10.74 | 12.84 |
| Distribution rate | 82.3% | 86.1% | 220% | 263% | 282% | 83.2% | 67.4% | 59.5% |
| Net sales 1 | 56,122 | 58,054 | 54,318 | 56,334 | 61,160 | 67,234 | 72,762 | 78,239 |
| EBITDA 1 | 29,018 | 30,961 | 25,545 | 24,104 | 24,483 | 32,835 | 36,986 | 40,815 |
| EBIT 1 | 28,215 | 30,183 | 24,793 | 23,340 | 23,721 | 31,881 | 36,309 | 40,029 |
| Net income 1 | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 | 14,291 | 19,187 | 22,412 |
| Net Debt 1 | 66,854 | 54,042 | 46,571 | 61,589 | 59,740 | 55,003 | 46,427 | 34,165 |
| Reference price 2 | 135.40 | 161.61 | 154.97 | 177.70 | 228.49 | 248.08 | 248.08 | 248.08 |
| Nbr of stocks (in thousands) | 1,767,880 | 1,767,880 | 1,765,537 | 1,767,140 | 1,767,385 | 1,766,793 | - | - |
| Announcement Date | 2/2/22 | 9/2/23 | 2/2/24 | 31/1/25 | 4/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 30.1x | 7.34x | 15.02x | 2.76% | 438B | |
| 34.92x | 12.63x | 25.81x | 0.57% | 1,060B | |
| 27.42x | 6.3x | 17.1x | 2.08% | 619B | |
| 17.98x | 4.45x | 11.01x | 2.97% | 333B | |
| 21.52x | 5.52x | 13.36x | 2.86% | 282B | |
| 21.56x | 4.53x | 12.65x | 1.94% | 267B | |
| 14.17x | 5.3x | 10.9x | 3.52% | 218B | |
| 23.78x | 6.31x | 11.12x | 2.78% | 196B | |
| -46.02x | 5.6x | 31.12x | 2.5% | 161B | |
| 12.29x | 3.03x | 7.56x | 7.14% | 138B | |
| Average | 15.77x | 6.10x | 15.57x | 2.91% | 371.17B | |
| Weighted average by Cap. | 23.44x | 7.67x | 17.77x | 2.19% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABBV Stock
- Valuation AbbVie Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition